journal article·2024-03-11

pH-Responsive Hyaluronic Acid Nanomicelles for Photodynamic /Chemodynamic Synergistic Therapy Trigger Immunogenicity and Oxygenation

Hui Zhang, Yujun Bao, Guanghao Li, Siqi Li, Xiong Zhang, Changhong Guo, Xiaodan Wu, Yingxue Jin

Publisher page

Abstract

Cancer metastasis and invasion are closely related to tumor cell immunosuppression and intracellular hypoxia. Activation of immunogenicity and intracellular oxygenation are effective strategies for cancer treatment. In this study, multifunctional nanomicelle hyaluronic acid and cinnamaldehyde is self-assembled into nanomicelles (HPCNPs) were constructed for immunotherapy and tumor cell oxygenation. The Schiff base was constructed of HPCNPs with pyropheophorbide a–Cu (PPa–Cu). HPCNPs are concentrated in tumor sites under the guidance of CD44 proteins, and under the stimulation of tumor environment (weakly acidic), the Schiff base is destroyed to release free PPa. HPCNPs with photodynamic therapeutic functions and chemokinetic therapeutic functions produce a large number of reactive oxygen species ( 1 O 2 and • OH) under exogenous (laser) and endogenous (H 2 O 2 ) stimulations, causing cell damage, and then inducing immunogenic cell death (ICD). ICD markers (CRT and ATP) and immunoactivity markers (IL-2 and CD8) were characterized by immunofluorescence. Downregulation of Arg1 protein proved that the tumor microenvironment changed from immunosuppressive type (M2) to antitumor type (M1). The oxidation of glutathione by HPCNP cascades to amplify the concentration of reactive oxygen species. In situ oxygenation by HPCNPs based on a Fenton-like reaction improves the intracellular oxygen level. In vitro and in vivo experiments demonstrated that HPCNPs combined with an immune checkpoint blocker (α-PD-L1) effectively ablated primary tumors, effectively inhibited the growth of distal tumors, and increased the oxygen level in tumor cells.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Molecular Cytogenetics and Genetic Breeding of Heilongjiang Province, College of Life Science and Technology, Harbin Normal University, Harbin 150025, China

Key Laboratory for Photonic and Electronic Bandgap Materials, Ministry of Education, College of Chemistry & Chemical Engineering, Harbin Normal University, Harbin 150025, China

Funding

Harbin Normal University · Natural Science Foundation of Heilongjiang Province

References (37)

Show source-provided references
1. 10.7150/thno.6730010.7150/thno.67300 ↗
2. 10.1002/ijc.3171710.1002/ijc.31717 ↗
3. 10.1016/j.cclet.2020.02.00710.1016/j.cclet.2020.02.007 ↗
4. 10.1002/adma.20200478810.1002/adma.202004788 ↗
5. 10.1039/C8TB02159G10.1039/C8TB02159G ↗
6. 10.1002/smll.20190235210.1002/smll.201902352 ↗
7. 10.3389/fphar.2018.0123010.3389/fphar.2018.01230 ↗
8. 10.1016/j.addr.2015.01.00210.1016/j.addr.2015.01.002 ↗
9. 10.1038/s41598-017-09815-910.1038/s41598-017-09815-9 ↗
10. 10.1016/j.addr.2020.06.00510.1016/j.addr.2020.06.005 ↗
11. 10.1016/j.addr.2018.07.00710.1016/j.addr.2018.07.007 ↗
12. 10.1039/C6CS00592F10.1039/C6CS00592F ↗
13. 10.1039/D0TB02360D10.1039/D0TB02360D ↗
14. 10.1016/j.biomaterials.2020.12027810.1016/j.biomaterials.2020.120278 ↗
15. 10.1021/acs.accounts.0c0031310.1021/acs.accounts.0c00313 ↗
16. 10.1002/adfm.20210024310.1002/adfm.202100243 ↗
17. 10.1016/j.jcis.2020.12.02810.1016/j.jcis.2020.12.028 ↗
18. 10.1016/j.cclet.2020.06.03110.1016/j.cclet.2020.06.031 ↗
19. 10.1016/j.ejphar.2014.07.02510.1016/j.ejphar.2014.07.025 ↗
20. 10.1016/j.jconrel.2020.08.00110.1016/j.jconrel.2020.08.001 ↗
21. 10.1039/d2tb00789d10.1039/d2tb00789d ↗
22. 10.3389/fmicb.2017.0071310.3389/fmicb.2017.00713 ↗
23. 10.1016/j.ccr.2020.21367610.1016/j.ccr.2020.213676 ↗
24. 10.1002/adfm.20190501310.1002/adfm.201905013 ↗
25. 10.1016/j.jpain.2016.05.00410.1016/j.jpain.2016.05.004 ↗
26. 10.1016/j.cej.2020.12462810.1016/j.cej.2020.124628 ↗
27. 10.1016/j.cclet.2022.05.06610.1016/j.cclet.2022.05.066 ↗
28. 10.1016/j.jcis.2021.11.12510.1016/j.jcis.2021.11.125 ↗
29. 10.1039/d0qi01249a10.1039/d0qi01249a ↗
30. 10.1016/j.jcis.2023.03.06510.1016/j.jcis.2023.03.065 ↗
31. 10.1016/j.ijbiomac.2023.12400310.1016/j.ijbiomac.2023.124003 ↗
32. 10.1021/acs.bioconjchem.0c0069410.1021/acs.bioconjchem.0c00694 ↗
33. 10.1002/adma.20200464710.1002/adma.202004647 ↗
34. 10.3390/ijms2403265510.3390/ijms24032655 ↗
35. 10.1038/ncomms1319310.1038/ncomms13193 ↗
36. 10.1016/j.fct.2013.10.04310.1016/j.fct.2013.10.043 ↗
37. 10.1186/s13045-021-01102-510.1186/s13045-021-01102-5 ↗